CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.9% – Should You Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP) shares were down 1.9% on Thursday . The company traded as low as $41.53 and last traded at $43.02. Approximately 311,635 shares traded hands during trading, a decline of 86% from the average daily volume of 2,252,937 shares. The stock had previously closed at $43.84.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. The Goldman Sachs Group decreased their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Truist Financial increased their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Stock Down 1.1 %

The firm has a market cap of $3.72 billion, a P/E ratio of -9.92 and a beta of 1.67. The firm has a fifty day moving average of $42.63 and a 200-day moving average of $45.84.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In related news, Director John Greene acquired 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Wood Tarver Financial Group LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $30,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $36,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.